Haleon Boosts US Sales by Targeting Side Effects of GLP-1 Weight-Loss Drugs

Consumer health company Haleon is successfully increasing U.S. sales by marketing its over-the-counter products to the rapidly growing number of consumers using GLP-1 weight-loss drugs. The company is strategically placing products that alleviate common side effects in dedicated retail displays, capitalizing on the pharmaceutical megatrend.

A New In-Store Strategy

Haleon, the maker of Advil, TUMS, and Biotène, is working with retailers including CVS Pharmacy to create curated shelf space for users of GLP-1 medications like Wegovy and Zepbound. These drugs are known to have side effects such as nausea, constipation, and abdominal pain, which Haleon's products can help manage.

A company spokesperson stated that this "dual placement" strategy—featuring products in both their regular aisles and in new "GLP-1 destination sets"—delivered an average 24% sales lift per store during the first quarter. The spokesperson added that "Haleon holds the majority of GLP-1 shelf space at CVS."

Tapping a Growing Market

Ad

The move targets a significant and expanding demographic. According to analytics firm Gallup, approximately 11% of Americans are currently taking GLP-1 drugs for weight loss. By addressing the common side effects of these popular medications, Haleon is positioning its existing portfolio to serve a new and specific consumer need.

CVS Pharmacy confirmed it is adapting to this trend, stating it has "expanded its product assortment and is highlighting CVS brand and national brand over-the-counter products to help make managing side effects easier." The retailer did not comment directly on its arrangement with Haleon.

Broader Retail Push

The strategy appears to be part of a broader push by the London-listed company. The Haleon spokesperson confirmed it has also held discussions with retail giants Walmart and Target about its GLP-1 in-store strategy, though the outcome of those talks was not disclosed. This initiative demonstrates how consumer health companies are adapting to capture ancillary revenue from major shifts in the pharmaceutical landscape.